PL2556071T3 - Inhibitory kinaz i ich zastosowanie w leczeniu raka - Google Patents
Inhibitory kinaz i ich zastosowanie w leczeniu rakaInfo
- Publication number
- PL2556071T3 PL2556071T3 PL11764988T PL11764988T PL2556071T3 PL 2556071 T3 PL2556071 T3 PL 2556071T3 PL 11764988 T PL11764988 T PL 11764988T PL 11764988 T PL11764988 T PL 11764988T PL 2556071 T3 PL2556071 T3 PL 2556071T3
- Authority
- PL
- Poland
- Prior art keywords
- treating cancer
- kinase inhibitors
- kinase
- inhibitors
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32132910P | 2010-04-06 | 2010-04-06 | |
| US32133210P | 2010-04-06 | 2010-04-06 | |
| PCT/CA2010/000518 WO2010115279A1 (en) | 2009-04-06 | 2010-04-06 | Kinase inhibitors and method of treating cancer with same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2556071T3 true PL2556071T3 (pl) | 2017-02-28 |
Family
ID=44761967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11764988T PL2556071T3 (pl) | 2010-04-06 | 2011-04-06 | Inhibitory kinaz i ich zastosowanie w leczeniu raka |
Country Status (25)
| Country | Link |
|---|---|
| US (9) | US8921545B2 (pl) |
| EP (2) | EP2556070B1 (pl) |
| JP (1) | JP5442906B2 (pl) |
| KR (1) | KR101782668B1 (pl) |
| CN (1) | CN102892766B (pl) |
| AU (1) | AU2011238384B2 (pl) |
| BR (1) | BR112012025496B1 (pl) |
| CY (1) | CY1118610T1 (pl) |
| DK (1) | DK2556071T3 (pl) |
| EA (1) | EA023173B1 (pl) |
| ES (2) | ES2639757T3 (pl) |
| HR (1) | HRP20161498T1 (pl) |
| HU (1) | HUE030651T2 (pl) |
| IL (1) | IL221556A (pl) |
| LT (1) | LT2556071T (pl) |
| ME (1) | ME02545B (pl) |
| MX (1) | MX2012011516A (pl) |
| NZ (1) | NZ602350A (pl) |
| PL (1) | PL2556071T3 (pl) |
| PT (1) | PT2556071T (pl) |
| SG (1) | SG183875A1 (pl) |
| SI (1) | SI2556071T1 (pl) |
| SM (1) | SMT201600430B (pl) |
| TW (1) | TWI516262B (pl) |
| WO (2) | WO2011123947A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101970426A (zh) * | 2007-12-21 | 2011-02-09 | 大学健康网络 | 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂 |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| ES2639757T3 (es) | 2010-04-06 | 2017-10-30 | University Health Network | Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales |
| WO2012000103A1 (en) * | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) * | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| ES2712717T3 (es) * | 2012-07-27 | 2019-05-14 | Sato Pharma | Compuesto de difluorometileno |
| DK3057965T3 (en) * | 2013-10-18 | 2019-04-01 | Univ Health Network | SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR |
| MX357763B (es) * | 2013-10-18 | 2018-07-23 | Univ Health Network | Tratamiento para cancer pancreatico. |
| CN104130175A (zh) * | 2014-06-13 | 2014-11-05 | 天津科技大学 | 不同位置取代吲哚酮类衍生物及其应用 |
| CN110072865B (zh) | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
| CN108947961B (zh) * | 2017-05-18 | 2021-06-04 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
| CN111225670A (zh) * | 2017-09-08 | 2020-06-02 | 大学健康网络 | 抑制Polo样激酶4的组合疗法 |
| EP3876939A4 (en) | 2018-11-07 | 2022-08-10 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020215155A1 (en) * | 2019-04-24 | 2020-10-29 | University Health Network | Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
| IL293623A (en) * | 2019-12-06 | 2022-08-01 | Univ Health Network | Treatment of acute myeloid leukemia or myelodysplastic syndrome |
| US11691963B2 (en) | 2020-05-06 | 2023-07-04 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CN112250614B (zh) | 2020-10-20 | 2022-02-01 | 苏州大学 | 3-螺三元环吲哚酮衍生物的合成方法 |
| TW202241889A (zh) | 2020-12-23 | 2022-11-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑 |
| TW202300485A (zh) * | 2021-03-02 | 2023-01-01 | 大陸商上海齊魯製藥研究中心有限公司 | Plk4抑制劑及其用途 |
| IL308346A (en) | 2021-05-11 | 2024-01-01 | Oric Pharmaceuticals Inc | Polo like kinase 4 inhibitors |
| CN115677682B (zh) * | 2021-07-30 | 2023-07-18 | 上海齐鲁制药研究中心有限公司 | 螺环类plk4抑制剂及其用途 |
| AU2022388555A1 (en) | 2021-11-09 | 2024-05-02 | Ajax Therapeutics, Inc. | 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12162881B2 (en) | 2021-11-09 | 2024-12-10 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of JAK2 |
| WO2024006379A1 (en) * | 2022-06-30 | 2024-01-04 | Axonis Therapeutics, Inc. | Methods and compounds for inhibiting mkk7 enzymes |
| CR20250419A (es) | 2023-04-06 | 2025-10-07 | Pfizer | Compuestos de derivados de ácido indazol propiónico sustituidos y usos de estos |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3310891A1 (de) | 1983-03-25 | 1984-09-27 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue indolinon-(2)-derivate, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und zwischenprodukte |
| US5182397A (en) * | 1990-05-31 | 1993-01-26 | American Cyanamid Company | Aryloxyspiroalkylindolinone herbicides |
| GB9507298D0 (en) | 1995-04-07 | 1995-05-31 | Pharmacia Spa | Substituted indolylmethylene-oxindale analogues as tyrosine kinase inhibitors |
| US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| JP2001503736A (ja) | 1996-08-23 | 2001-03-21 | スージェン・インコーポレーテッド | 疾病の治療のためのインドリノンのコンビナトリアルライブラリーおよび関連する生成物および方法 |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
| JP2002522452A (ja) | 1998-08-04 | 2002-07-23 | スージェン・インコーポレーテッド | 蛋白質キナーゼの調節剤３−メチリデニル−２−インドリノン |
| WO2000056709A1 (en) | 1999-03-24 | 2000-09-28 | Sugen, Inc. | Indolinone compounds as kinase inhibitors |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2410509A1 (en) | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| AU2003241925A1 (en) | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US7148249B2 (en) | 2002-09-12 | 2006-12-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments |
| WO2004037247A1 (en) * | 2002-10-21 | 2004-05-06 | Irm Llc | Oxindoles with anti-hiv activity |
| WO2005058309A1 (en) | 2003-12-16 | 2005-06-30 | Leo Pharma A/S | Novel therapeutic use of indolinone derivatives |
| US20050211590A1 (en) | 2004-03-26 | 2005-09-29 | Mcclure George K | Protective cover for medical devices |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US20070135509A1 (en) | 2005-12-09 | 2007-06-14 | Blackburn Thomas P | Indolone compounds useful to treat cognitive impairment |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| WO2007109026A2 (en) | 2006-03-15 | 2007-09-27 | The Trustees Of Columbia University In The City Of New York | Pten compositions and methods for detecting breast cancer |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| CA2690567A1 (en) * | 2007-06-12 | 2008-12-18 | Boehringer Ingelheim International Gmbh | 3-hetrocyclylidene-indolinone derivatives as inhibitors of specific cell cycle kinases |
| US8026234B2 (en) | 2007-09-25 | 2011-09-27 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| WO2009065232A1 (en) | 2007-11-20 | 2009-05-28 | University Health Network | Cancer diagnostic and therapeutic methods that target plk4/sak |
| CN101970426A (zh) | 2007-12-21 | 2011-02-09 | 大学健康网络 | 吲唑基、苯并咪唑基、苯并三唑基取代的二氢吲哚酮衍生物作为癌症治疗中有用的激酶抑制剂 |
| JP2009173629A (ja) * | 2007-12-21 | 2009-08-06 | Banyu Pharmaceut Co Ltd | Ｒｓｋ１阻害作用を有する新規スピロインダン誘導体 |
| US8765791B2 (en) * | 2008-03-11 | 2014-07-01 | University Health Network | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist |
| EP2108641A1 (en) * | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
| EP2113503A1 (en) * | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
| WO2010008731A1 (en) | 2008-06-16 | 2010-01-21 | Tigris Pharmaceuticals, Inc. | Methods for determining sensitivity to aminoflavones |
| DE102008040187A1 (de) * | 2008-07-04 | 2010-01-07 | Robert Bosch Gmbh | Sensorelement, Verfahren zu seiner Herstellung sowie Verwendung |
| AU2009279936A1 (en) | 2008-08-05 | 2010-02-11 | Banyu Pharmaceutical Co., Ltd. | Therapeutic compounds |
| EP2417127B1 (en) | 2009-04-06 | 2014-02-26 | University Health Network | Kinase inhibitors and method of treating cancer with same |
| WO2011069298A1 (en) * | 2009-12-11 | 2011-06-16 | F. Hoffmann-La Roche Ag | Novel cyclopropane indolinone derivatives |
| JP5056876B2 (ja) | 2010-03-19 | 2012-10-24 | Ｊｆｅスチール株式会社 | 冷間加工性と焼入れ性に優れた熱延鋼板およびその製造方法 |
| ES2639757T3 (es) | 2010-04-06 | 2017-10-30 | University Health Network | Síntesis de 2-(1H-indazol-6-il)espiro[ciclopropan-1,3'-indolin]-2'-onas quirales |
| WO2012000103A1 (en) * | 2010-07-02 | 2012-01-05 | University Health Network | Methods of targeting pten mutant diseases and compositions therefor |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| JP5808818B2 (ja) | 2010-11-25 | 2015-11-10 | ラツィオファーム・ゲーエムベーハー | アファチニブの新規塩及び多形形態 |
| EP2681216B1 (en) * | 2011-02-28 | 2017-09-27 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| GB201109966D0 (en) | 2011-06-10 | 2011-07-27 | Cancer Res Inst Royal | Materials and methods for treating pten mutated or deficient cancer |
| WO2013053051A1 (en) | 2011-10-12 | 2013-04-18 | University Health Network | Indazole compounds as kinase inhibitors and method of treating cancer with same |
| DK3057965T3 (en) | 2013-10-18 | 2019-04-01 | Univ Health Network | SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR |
| MX357763B (es) | 2013-10-18 | 2018-07-23 | Univ Health Network | Tratamiento para cancer pancreatico. |
-
2011
- 2011-04-06 ES ES11764989T patent/ES2639757T3/es active Active
- 2011-04-06 CN CN201180018148.2A patent/CN102892766B/zh active Active
- 2011-04-06 HU HUE11764988A patent/HUE030651T2/en unknown
- 2011-04-06 DK DK11764988.9T patent/DK2556071T3/en active
- 2011-04-06 US US13/639,648 patent/US8921545B2/en active Active
- 2011-04-06 PT PT117649889T patent/PT2556071T/pt unknown
- 2011-04-06 SG SG2012065090A patent/SG183875A1/en unknown
- 2011-04-06 LT LTEP11764988.9T patent/LT2556071T/lt unknown
- 2011-04-06 NZ NZ602350A patent/NZ602350A/en unknown
- 2011-04-06 JP JP2013502966A patent/JP5442906B2/ja active Active
- 2011-04-06 MX MX2012011516A patent/MX2012011516A/es active IP Right Grant
- 2011-04-06 WO PCT/CA2011/000387 patent/WO2011123947A1/en not_active Ceased
- 2011-04-06 ES ES11764988.9T patent/ES2603613T3/es active Active
- 2011-04-06 EA EA201270752A patent/EA023173B1/ru unknown
- 2011-04-06 WO PCT/CA2011/000386 patent/WO2011123946A1/en not_active Ceased
- 2011-04-06 BR BR112012025496-0A patent/BR112012025496B1/pt active IP Right Grant
- 2011-04-06 EP EP11764989.7A patent/EP2556070B1/en active Active
- 2011-04-06 US US13/081,254 patent/US8263596B2/en active Active
- 2011-04-06 EP EP11764988.9A patent/EP2556071B1/en active Active
- 2011-04-06 AU AU2011238384A patent/AU2011238384B2/en active Active
- 2011-04-06 ME MEP-2016-265A patent/ME02545B/me unknown
- 2011-04-06 TW TW100111767A patent/TWI516262B/zh active
- 2011-04-06 HR HRP20161498TT patent/HRP20161498T1/hr unknown
- 2011-04-06 PL PL11764988T patent/PL2556071T3/pl unknown
- 2011-04-06 SI SI201131015A patent/SI2556071T1/sl unknown
- 2011-04-06 KR KR1020127029064A patent/KR101782668B1/ko active Active
-
2012
- 2012-06-21 US US13/529,542 patent/US8481533B2/en active Active
- 2012-08-21 IL IL221556A patent/IL221556A/en active IP Right Grant
-
2013
- 2013-07-03 US US13/935,021 patent/US9139563B2/en active Active
-
2014
- 2014-12-23 US US14/580,658 patent/US9579327B2/en active Active
-
2015
- 2015-08-11 US US14/823,057 patent/US9907800B2/en active Active
-
2016
- 2016-11-17 CY CY20161101184T patent/CY1118610T1/el unknown
- 2016-11-24 SM SM201600430T patent/SMT201600430B/it unknown
-
2017
- 2017-02-23 US US15/440,548 patent/US9796703B2/en active Active
- 2017-10-23 US US15/790,847 patent/US10077255B2/en active Active
-
2018
- 2018-02-22 US US15/902,143 patent/US10358436B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2556071T3 (pl) | Inhibitory kinaz i ich zastosowanie w leczeniu raka | |
| ZA201300255B (en) | Morpholino pyrimidines and their use in therapy | |
| IL238400A0 (en) | Triazolopyrazines as brd4 inhibitors for use in cancer therapy | |
| IL214626A0 (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| SG11201404596UA (en) | Cdk8/cdk19 selective inhibitors and their use in anti-metastatic and chemopreventative methods for cancer | |
| ZA201207574B (en) | Phytocannabinoids in the treatment of cancer | |
| ZA201404965B (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
| IL228847A0 (en) | il1r1 inhibitors and their use in cancer treatment | |
| IL232353B (en) | An inhibitor of the nedd8 mecatenase and a hypomethylated agent for use in cancer therapy | |
| ZA201204423B (en) | Neuregulin antagonists and use thereof in treating cancer | |
| IL218182A0 (en) | Kinase inhibitors, prodrug forms thereof and their use in therapy | |
| HRP20171280T1 (hr) | Pirazolilgvanidinski inhibitori f1f0-atpaze i njihova upotreba u terapiji | |
| IL202307A0 (en) | Multikinase inhibitors for use in the treatment of cancer | |
| IL233080B (en) | Bisarylsulfonamides used to treat inflammation and cancer | |
| EP2537031A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | |
| GB201718726D0 (en) | Phytocannabinoids in the treatment of cancer | |
| SG11201406199TA (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| HK1180315A (en) | Kinase inhibitors and their use in treating cancer | |
| IL225959A0 (en) | Methods and preparations for diagnosis and treatment @ בסרטן | |
| ZA201105917B (en) | Prodrug forms of kinase inhibitors and their use in therapy | |
| HUP1000688A2 (en) | Use of trifluoro-phthalimides in the treatment of cancer | |
| IL234913A0 (en) | Cancer treatment methods using pi3k inhibitor and mek monitoring |